Diagnostic imaging group Bracco Imaging SpA signed a licensing and collaboration agreement with Philochem AG. The companies will focus on developing and commercializing a small molecule for diagnostic imaging applications that can detect metastatic solid tumors in cancer patients.
Bracco Imaging SpA. is buying prostate cancer imaging specialist Blue Earth Diagnostics Ltd. for $450 million, acquiring full rights to Axumin (F18-fluciclovine), a PET radiocontrast agent originally developed by Chicago-based GE Healthcare.
